Scorpi18 | Market Insights
6.29K subscribers
5.37K photos
59 videos
24 files
3.57K links
Insights and analysis of the global financial market by investment advisor Sergio Shalamov.

Note: This is not an investment advice.

Contact: @invoyager

Buy ads: https://telega.io/c/scorpi18
Download Telegram
๐Ÿ’ฅ๐Ÿ‡บ๐Ÿ‡ธ#PFE #BNTX #vaccine
EMA announces additional vaccine production capacity from Biontech/Pfize
โš ๏ธ๐Ÿ‡บ๐Ÿ‡ธ#PFE #BNTX #vaccine #sideeffects
Israel says likely link between Pfizer COVID-19 vaccine and myocarditis of young men - RTRS
๐Ÿ’ฅ๐Ÿ‡บ๐Ÿ‡ธ#PFE #BNTX #vaccine #britain
UK regulator approves Pfizer vaccine for 12-15 year old
๐Ÿ’ฅ๐Ÿ‡บ๐Ÿ‡ธ#PFE #BNTX #vaccine
Biontech plans to produce 4B doses of vaccine in 2022 - Handelsblatt
๐ŸŒŽ#vaccine #world #G7
G7 leaders agree to speed up production and supply of coronavirus vaccines around the world

#PFE #BNTX #MRNA #JNJ #AZN #MRK
๐Ÿ‡ฎ๐Ÿ‡ณ#RDY #generic #PFE
Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill
๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ง#PFE #GSK
Pfizer plans to exit its 32% stake in Haleon, a consumer health joint venture with GSK
๐Ÿ’ฅ๐ŸŒ#bigpharma #biotech #world #businessmodel
Taken together, the pricing innovations and scientific advances has notably shifted in focus Big Pharma firms to biotech.

JAMA: the median list price of a drug first marketed in 2021 was $180,007 per year, up from $2,115 in 2008. Between 2008 and 2013, only 9% of newly launched drugs cost $150,000 a year or more; in 2020 and 2021, 47% of new drugs cost that much.

Biologics canโ€™t be copied when their exclusivities end; rather, competitors must make so-called biosimilars, which so far have not proven to be as devastating to the revenue of the branded drugs as traditional generics. #generic #biosimilar

โ€ฆa more sustainable business model long term

#GSK #PFE #BMY #LLY #JNJ #TEVA
๐Ÿ‡บ๐Ÿ‡ธ#PFE #mna
Pfizer to buy 8.1% of vaccines company Valneva
โ€”โ€”โ€”โ€”โ€”-
Big Pharma firms shifted focus in biotech - details
โšก๏ธ๐Ÿ‡บ๐Ÿ‡ธ#PFE #report
Pfizer Q2 22 Earnings:
- Adj EPS: $2.04 (est $1.81)
- Revenue: $27.7B (est $26.31B)
- Raises Year 2022 Financial Guidance For Rev & Adj EPS
- Doesnโ€™t Anticipate Additional Share Repurchases
- Still See FY Rev $98.0B to $102.0B (est $103.44B)
๐Ÿ‡บ๐Ÿ‡ธ#GBT #PFE #mna
Pfizer reaches $5.4B deal for Global Blood Therapeutics $68.50/share